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Introduction: Recent studies suggest an important role of the cystic fibrosis transmembrane conductance regulator
gene in the development of pancreatitis. It occurs approximately in 20% of patients with cystic fibrosis and almost
exclusively in pancreatic sufficient people. Newborn screening and improved panels of deoxyribonucleic acid
mutation analysis techniques are revealing more rare and nonclassical pictures of the disease, generally associated
with pancreatic sufficiency and with an increased risk of developing pancreatitis. Mutations R1438 and Y1032 are
considered rare mutations, and, when singularly associated with ΔF508, lead to a mild phenotype with pancreatic
sufficiency and no detectable respiratory involvement.
Case presentation: We present the case of a Caucasian girl, aged six years, whose genotype was characterized by
three different mutations ΔF508, R1438W and Y1032C, never reported, together, in the same patient. She presented
with a positive immunoreactive trypsinogen screening, a borderline sweat test, and, in the first years, a favorable
pulmonary course, and pancreatic sufficiency. At the age of six years, she presented with a sudden episode of acute
abdominal pain, anorexia and fever. A diagnosis of pancreatitis was made after clinical and laboratory examinations.
Venous rehydration, bowel rest and therapy with ursodeoxycholic acid resulted in complete remission.
The treatment was successful, with normalization of her symptoms and laboratory parameters within four weeks.
Conclusion: There has been a vast expansion in the understanding of the wide range of phenotypes associated
with cystic fibrosis transmembrane conductance regulator dysfunction since the discovery of the cystic fibrosis
transmembrane conductance regulator gene. The genotype-phenotype correlation in pancreatitis is rare compared
to other organ manifestations, since this is seen almost exclusively among pancreatic sufficient patients with cystic
fibrosis. Our study supports that compound heterozygosis ΔF508-R1438W/Y1032C is a 'cystic fibrosis-causing
genotype' characterized by an immunoreactive trypsinogen positive screening, abnormal sweat chloride testing,
and pancreatic sufficiency, with an increased risk of acute pancreatitis at an early age.
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Cystic fibrosis (CF) is the most common, potentially lethal,
autosomal recessive disorder in western countries (1:2500
live births). The disease is caused by mutations in the gene
that encodes for the cystic fibrosis transmembrane con-
ductance regulator (CFTR) protein [1].
The exocrine pancreas is the most reliable phenotypic
barometer of CFTR function among all the organs affected* Correspondence: leonardi@unict.it
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reproduction in any medium, provided the or[2]. The relationship between the severity of the CFTR
genotype and the risk of pancreatitis has been well
established and it occurs almost exclusively in patients
with CF presenting with mild mutations and pancreatic
sufficient patients with CF, and not in patients with
pancreatic insufficiency (PI) [2].
Recently, deoxyribonucleic acid (DNA) mutation ana-
lysis is revealing new CFTR gene haplotypes but sample
size limitations make genotype-phenotype correlation
studies difficult [3,4].
To date, the presence of three different mutations in
the same patient is rarely reported and it represents aal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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We report a case of a seven-year-old girl, affected by
cystic fibrosis disease, who presented with acute pan-
creatitis at six years of age.
Case presentation
The patient, a Caucasian six-year-old girl, was born at
term by nonconsanguineous, healthy parents, with a birth
weight of 3.160kg. Her newborn screening test results for
cystic fibrosis, performed by immunoreactive trypsinogen
(IRT) measurement, were positive on the third and fifteenth
day. Her sweat test showed borderline results of chlorine
44mEq/L and 48mEq/L (normal value (n.v.) <40mEq/L).
The genetic analysis of the CFTR gene showed compound
heterozygosis of ΔF508-R1438W in cis and Y032C in trans
mutations (Table 1). In the first year's growth, her respira-
tory system and respiratory functions were normal. In fact,
at the age of six years, her weight was 20kg (35th percentile
for age), her body mass index (BMI) was 14.4 (24th per-
centile for age); at spirometry, her forced vital capacity
(FVC) was 90% and forced expiratory volume (FEV)1 92%,
and she had always presented with a low amount of fecal
elastase-1.
At six years old, the patient was treated for acute abdom-
inal pain, anorexia and fever. She presented with abdominal
pain radiating to the back, mild muscular guarding,
decreased bowel sounds and mild scleral icterus. Her
laboratory examination results showed an erythrocyte
sedimentation rate (ESR) of 51mm/h, increased values
of total bilirubin (2.67mg/dL) and direct bilirubin
1.80mg/dL, pancreatic amylase (305U/L, n.v. 0 to 46U/L)
and total amylases (465U/L, n.v. 28 to 100U/L) and lipase
(310U/L, n.v. 0 to 60U/L). An ultrasound evaluation of the
abdomen showed parenchymal hyperechogenity of the
pancreas with no images of biliary calculi, or hepatic alter-
ations. Venous rehydration, bowel rest and therapy with
ursodeoxycholic acid were successfully performed, with
normalization of her symptoms and laboratory parameters
within four weeks.
At present, general conditions are good. Her respira-
tory function is normal on spirometric evaluation, and
she is not presenting with bacterial colonization in the
respiratory tract. Pancreatic and digestive functions are
good: her weight is on the 25th percentile, her height isTable 1 Genotype of the patient
Cystic fibrosis transmembrane conductance regulator
gene haplotype
Mutation Patient Father Mother
ΔF508 ΔF508/+ +/+ ΔF508/+
R1438W R1438W /+ +/+ R1438W/+
Y1032C +/Y1032C +/Y1032C +/+
+ denotes the presence of the wild-type allele.on the 75th percentile, her pancreatic amylase value and
total amylases are within the normal range.
Discussion
Exocrine pancreas function is a reliable predictor of
overall CFTR function and disease severity. Most pa-
tients with CF carrying functionally severe mutations on
both alleles have a PI phenotype [2], while patients who
carry a mild mutation on at least one allele usually have
sufficient exocrine pancreatic function. However, while
pancreatic insufficiency is a recognized complication of
CF, symptomatic pancreatitis represents a rare manifest-
ation of CF, affecting <2% of patients. Specific CFTR
genotypes are significantly associated with pancreatitis
and paradoxically genotypes associated with otherwise
mild phenotypic effects have a greater risk [3]. Clinical
presentation of acute pancreatitis in patients with CF is
substantially similar to what happens in unaffected
people. Together with the 'common' risk factors (alcohol,
gallstones, hypercalcemia, hyperlipidemia, malnutrition,
abdominal trauma, drugs, infections and radiation), pan-
creatic sufficient patients with CF present an impaired
secretion of pancreatic enzymes due to obstructions in the
ducts caused by altered chlorine transportation.
Rosendahl et al. [5] investigated 660 patients affected
by chronic pancreatitis (CP) and found that combined
CF-causing variants increased CP risk 3.4-fold (P<0.001),
while non-CF-causing variants displayed a 1.5-fold over-
representation in patients (P=0.14). Trans-heterozygosity
increased CP risk, with an odds ratio (OR) of 38.7, with
43 out of 660 (6.5%) patients and three out of 1667
(0.2%) controls being trans-heterozygous (P<0.0001).
They stated that compound and trans-heterozygosity is
an overt risk factor for CP.
Our patient presented with a compound heterozygote
genotype, characterized by ΔF508/R1438W and Y1032C
mutations. It is not uncommon to find, in southern re-
gions of Italy, different combinations of mutations in the
same patients. Contrary to what happens in Northern
Europe, Italian ancestry varies from Caucasian to Arabic
and Middle Eastern population, and the different muta-
tions found are probably due to the higher allelic hetero-
geneity of the CFTR gene in Italian population. ΔF508
mutation, for instance, is found (in homozygosis or in
heterozygosis) in 50% of Italian patients with CF, while in
Northern Europe the percentage is higher (70%) [1].
ΔF508 has been the first recognized mutation of the
CFTR gene, its prevalence in Caucasian population is es-
timated at 2.8% and in homozygosis it is responsible for
more than 70% of the typical form of cystic fibrosis [1].
In our patient, in the same chromosome carrying the
ΔF508 mutation, a substitution of a thymine with a cyto-
sine in position 4444 of exon 24 (R1438W mutation) was
present. This mutation was first described by Seia et al. in
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due to respiratory symptoms. His sweat test was abnor-
mal (78mmol/L chloride), but he was pancreatic suffi-
cient and his growth and lung function results were
normal [6]. In Seia’s report, the S977F variant was iden-
tified on the same chromosome, while ΔF508 was identi-
fied on the other chromosome (compound heterozygosis
R1438W-S977F/ΔF508).
Similar to our patient, the association of ΔF508-
R1438W 'in cis' (together with E588V mutation in the
other allele) has been already described [7]. This geno-
type causes a positive IRT newborn screening and a mild
presentation of CF with pancreatic sufficiency and no
pulmonary disease.
In our patient, we found the rare Y1032C mutation in
the other chromosome. This mutation was first identi-
fied in a German patient affected by congenital bilateral
absence of vas deferens (CBAVD), who presented with a
compound heterozygosis Y1032C/ΔF508 [8]. The patient
presented with recurrent bronchitis and pancreatic suffi-
ciency. Ratbi et al. [9] also reported a CBAVD in another
patient affected by a compound heterozygosis Y1032C/
D1152H mutation.
Both Ren et al. [10] and Seia et al. [11] included
ΔF508/Y032C among the mutations causing a 'milder'
form of CF with no clinical symptoms, borderline sweat
test, pancreatic sufficiency and no pulmonary disease.
How the alteration in the CFTR protein caused by
R1438W and Y1032C may lead to a specific 'pancrea-
titis-causing' phenotype by the combination with a se-
vere mutation like ΔF508 is unknown, but to date the
combination of these two rarely reported mutations with
severe mutations has been never associated with acute
pancreatitis. It is consistent to think that the combination
of the mild deficit caused by these two mild mutations
(together with ΔF508) could have caused a temporary
obstruction of pancreatic ducts but not a complete pan-
creatic insufficiency.Conclusions
The apparent status of wellness of patients with CF with
mild mutations and genotype could mislead the caregivers
and let them ignore the possible onset of acute pancrea-
titis, more common in pancreatic sufficient patients.
Our study would support that compound heterozygosis
ΔF508-R1438W/Y1032C is a 'CF-causing mutation' char-
acterized by a positive IRT screening, borderline sweat
test, and pancreatic sufficiency, with a risk of acute pan-
creatitis at an early age.Consent
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